Hers and Mounjaro: Tirzepatide, Branded vs Compounded

Part of the PlexusDx Education Hub: clear, evidence-based coverage of GLP-1 and dual-agonist therapies, weight-management protocols, and the genetic variables driving individual results. Browse all Peptides & GLP-1 education

An independent editorial review. PlexusDx has no commercial relationship with Hers, Eli Lilly, or the brands named here, and no affiliate links or compensation are involved.

Hers is one of many telehealth programs in the GLP-1 and weight-management space. This review focuses on Mounjaro and its active compound tirzepatide, the branded-versus-compounded distinction, and the trial evidence and genetics that sit behind any dual-agonist decision. Fair-balance framing, not a buying recommendation. Current as of April 2026.

Mounjaro, tirzepatide, and the dual-agonist class

Mounjaro is the brand name for tirzepatide, a GIP/GLP-1 dual agonist that differs mechanistically from single-target GLP-1 receptor agonists such as semaglutide. Hers, the women's brand of Hims & Hers Health, operates as subscription telehealth; whether it offers branded tirzepatide, a compounded version, or a different GLP-1 compound is set by the program and shown on Hers's official website.

Branded Mounjaro versus compounded tirzepatide

There is a meaningful distinction between an FDA-approved brand product dispensed by a retail pharmacy and a compounded tirzepatide preparation from a 503A compounding pharmacy. Telehealth programs may route to either pathway depending on eligibility and availability. In both cases the workflow is the same: intake, a licensed clinician's review and eligibility decision, a routed prescription, and follow-up for titration and side effects.

What the SURMOUNT trials showed

Tirzepatide's evidence comes chiefly from the SURMOUNT program for weight management (The New England Journal of Medicine, 2022) and SURMOUNT-OSA for obstructive sleep apnea (NEJM, 2024); for context, the semaglutide STEP trials were published in NEJM in 2021. Populations and endpoints differ across these studies, and individual outcomes vary. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual agonist tirzepatide together define the category.

Access and pricing considerations

Pricing for Hers is published on its own site and depends on the compound, the subscription tier, and whether dispensing is brand or compounded. Across the telehealth GLP-1 market as of April 2026, monthly totals generally fall between roughly $200 and $700+, with wide variance. Verify current numbers at Hers's official website before committing.

The genetic layer beneath tirzepatide

Even the right compound is prescribed into biology no intake form captures. Telehealth programs like this one do not examine the upstream genetic architecture that shapes every GLP-1 response. Variants in FTO (the fat-mass and obesity-associated gene), GLP1R (the GLP-1 receptor gene, the direct target of every GLP-1 compound), MC4R (a melanocortin receptor central to satiety and energy balance), and TCF7L2 (a transcription factor tied to glucose homeostasis and GLP-1 secretion) map the baseline metabolic terrain any compound acts on. These are pathway-level markers. They do not predict response to a specific medication, but they describe the biology a clinician is prescribing into, context a prescription alone never captures.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What distinguishes the approach is that upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO and MC4R, and TCF7L2 that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Reading that profile alongside the protocol is the test before you invest approach, turning guesswork into an informed conversation with your healthcare provider.

Not affiliated: PlexusDx is not affiliated with Hers and has no commercial relationship with the companies reviewed in this article.

Related reading on PlexusDx: Eli Lilly Mounjaro Coupon, Mounjaro Pills, Mounjaro Price Without Insurance, Mounjaro Compound.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hers and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols, and this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach to tirzepatide: see the Weight Management Protocols, semaglutide and tirzepatide paired with the genetic context most telehealth programs omit. Or start upstream and take the Precision Peptide Genetic Test to understand your GLP-1 pathway first.

Frequently Asked Questions About Hers and Mounjaro

Does Hers prescribe Mounjaro?

Mounjaro is the brand name for tirzepatide, and which compounds a program offers is set by the brand and posted on its own site. Telehealth programs may dispense FDA-approved brand products or compounded tirzepatide depending on eligibility, so confirm the specific offering directly.

What is the difference between Mounjaro and compounded tirzepatide?

Mounjaro is the FDA-approved brand product dispensed by retail pharmacies, while compounded tirzepatide is prepared by 503A compounding pharmacies for individual patients. Formulation, availability, and cost differ between the two pathways, so verify which one applies before assuming a particular price or supply.

Is Mounjaro cash-pay or covered through this kind of program?

Compounded telehealth generally operates cash-pay, outside insurance billing, while branded coverage depends on your own plan. Because dispensing pathways differ, confirm on the brand's own site whether a program routes to brand or compounded tirzepatide and what the posted price includes.

Do genes influence tirzepatide outcomes?

Tirzepatide is a dual GIP/GLP-1 agonist, and pathway-level variants in FTO and MC4R, and TCF7L2 shape the baseline metabolism it acts on. These markers do not predict response to tirzepatide, but they add upstream context that no prescription, branded or compounded, captures.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education